Asthma

This study is the first to preliminarily show that a community pharmacist intervention can produce a positive effect on reducing SABA reliance and improvement of ICS adherence in patients with asthma.

SMART uses an ICS and a long-acting beta-2 agonist (LABA) product, giving patients 4 years and older with moderate to severe uncontrolled persistent asthma 1 inhaler for dual symptom relief.

With these findings contributing to the understanding of neighborhood-level asthma risks, the authors note next steps can involve identifying and addressing disparities.

Drug therapy workups may reveal candidates for immune therapy and provide chance for interventions.

The findings emphasize a need for guideline-based care delivery for patients with severe asthma, particularly for patients who are facing social disparities within health care.

The authors note that additional research needs to be conducted to confirm whether the findings are consistent in adult patients.

Investigators added that additional randomized trials are still needed to confirm the benefits of traditional Chinese medicine, either with or without conventional therapies.

Benralizumab was previously approved by the FDA in 2017 as an add-on maintenance therapy for patients 12 years and older.

Piezo1 is a protein produced by type 2 innate lymphoid cells when activated by an allergen and can limit the immune cell’s activity when triggered by a reaction.

The Asthma and Allergy Foundation of America applauded the efforts by AstraZeneca, saying accessibility and affordability can help reduce racial disparities in asthma.

The effects were strongest during the spring season and in the third trimester of pregnancy.

Investigators found that 1,1,1 trichloroethane; 2-nitropropane; and 2,4,6 trichlorophenol were significantly associated with asthma symptoms for 3 exposure periods.

The study showed no clinical differences for remission or asthma at age 28 years based on lung function, body mass index, daily smoking, exposure to parental tobacco smoke, or house dampness .

Individuals with persistent asthma and at least 1 complex comorbidity were more likely to use telemedicine, the results of the study showed.

AAO-HNSF guideline development group included 17 panel members, including experts from otolaryngology and allergy, those who have knowledge in clinical practice guideline development, and patient representatives.

Dupilumab (Dupixent; Sanofi) showed greater reductions in mucus plugs and greater improvements in airway volume and flow for individuals with uncontrolled moderate-to-severe asthma.

RSV can exacerbate asthma development by causing damage to the tissue in the airways, promoting inflammation and increasing airway hyper-responsiveness

The efficacy of biologics suggests a potential for biologic-based treatment for patients with asthma-chronic obstructive pulmonary disease overlap.

The new understanding of immune cells could not only contribute to the development of lung disease treatments, but treatments for other organ systems as well.

The study authors note that interventions to reverse frailty, such as screening and assessments to identify issues, can help in the management of COPD and asthma and lead to better prognoses.

The study results demonstrated that 92% of patients treated with benralizumab were able to safely reduce inhaled steroid dose, and more than 60% could stop use entirely.

The study authors note that the Best ACT-S questionnaire complements the Best ACT-P questionnaire, a previously developed questionnaire that assesses preschool-aged patients with asthma.

The study also showcases a significant decline in asthma mortality rates in China, which were previously higher than the United States from 1990 to 2019.